Celgene Corporation announced on July 19 that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behcet’s disease. Otezla, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only…...
Vasculitis Expert Receives the Vaccine
Vasculitis Expert Receives the Vaccine Dr. Carol Langford, Director of the Cleveland Clinic Center for Vasculitis Care and Research, received her first dose of a Covid-19 vaccine on New Year’s Eve. Dr. Langford is recognized worldwide for her clinical care and research in the field of vasculitis. Dr. Langford studies…...
Recruiting: Efficacy and Safety of Benralizumab in EGPA compared to Mepolizumab (MANDARA)
Brief Summary: This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive…...
Leading Vasculitis Physician-Scientist Receives Covid-19 Vaccine
Dr. Peter Merkel, Director of the University of Pennsylvania Vasculitis Center and Co-Principal Investigator of the Vasculitis Patient-Powered Research Network, received his first dose of a COVID-19 vaccine just before New Year’s Eve. Dr. Merkel says “I am excited that the vaccine will become increasingly available to everyone, especially patients…...
Pitt Scientists Identify Genetic Risks of Rare Inflammatory Disease
PITTSBURGH, Dec. 11, 2020 – In a paper published today in the American Journal of Human Genetics, a group of international collaborators led by researchers from the University of Pittsburgh School of Medicine identified new genetic associations that can predict individual susceptibility to a rare inflammatory disease called Takayasu arteritis.…...
Scientists use Clues in the Human Genome to Discover new Inflammatory Syndrome
“Our team of researchers at the NIH discovered a new form of vasculitis and called it VEXAS. VEXAS is caused by genetic mutations in a portion of a patient’s blood cells. Before we knew about VEXAS, these patients were diagnosed with other forms of vasculitis, such as relapsing polychondritis, polyarteritis…...
